GlobeNewswire by notified

Dave Cantin Group Announces Investment from Kaltroco, Fueling the Continued Growth of Auto Industry’s Leading M&A Advisory Firm


Partnership will Set the Stage for DCG’s Industry, Geographic and Services Expansion

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) --  The Dave Cantin Group (“DCG” or “the Company”), a leading advisor to retail automotive groups and their owners, announced today that it received a significant minority investment from Kaltroco, a private investment company backed by the family of Steve Koltes, a co-founder of CVC Capital Partners. Kaltroco was founded in 1994 as a vehicle to invest in private companies and is committed to supporting the long-term growth of high-quality middle-market businesses. Financial terms were not disclosed.  

DCG annually advises on over $1 billion in gross transaction volume and has advised on hundreds of transactions since its founding in 2017. Kaltroco’s investment will support the next stage of DCG’s growth and development, as the Company builds upon its leadership position in the automotive advisory space. Plans for strategic investment include continued expansion into adjacent industry verticals such as motorcycle (Harley-Davidson), recreational vehicle (RV), powersports, and heavy truck, further growth of the Company’s geographic footprint, and the launch of enhanced advisory offerings.

“Our partnership with Kaltroco is truly transformational for DCG and will be a key differentiator for us in the dealer-driven advisory space,” said Dave Cantin, president and CEO of DCG. “While DCG is already one of the largest dealership-focused advisory companies in North America, we are confident that Kaltroco’s new capital, relationships and strategic counsel will further boost our growth trajectory. There is tremendous demand today for our services as public, private and institutional dealership owners look for guidance with succession planning and evaluation services, in addition to buy-side and sell-side advisory assignments. Our expansion will benefit DCG’s clients and employees alike and we are excited to pursue the next phase of our growth with the Kaltroco team at our side.”

“We are exceptionally impressed by all that Dave and his team have accomplished in the six short years since DCG was founded. We are excited by the Company’s many opportunities for continued growth, and we look forward to supporting management as they pursue their key value creation objectives in the years to come,” said Kenneth Hammond, Chief Investment Officer for Kaltroco. “Kaltroco has a long history of supporting fast-growing service businesses with unique and disruptive service models, and it was clear from our earliest conversations with Dave and his team that DCG is a true innovator in its industry, with a thoughtfully developed and distinctive service approach that offers differentiated benefits to the Company’s auto dealership clients. We are eager to work with Dave and the DCG team as we look to take advantage of many enticing opportunities in the sector.”

DCG was founded in 2017 by Mr. Cantin, who has held various leadership roles within the automotive industry for more than two decades. With deep roots across the automotive industry, DCG is supported by one of the largest and most experienced teams in the industry. The Company recently bolstered its senior leadership team with the addition of Brian Gordon as Chief Business and Marketing Officer, Stephen Jones as Chief Development Officer, and the promotions of Brian Traugott and Tony Karabon to Co-Executive Vice Presidents. All members of DCG’s senior executive team are shareholders in the business, signaling their shared, long-term commitment to the Company’s growth and success.

Baird served as the exclusive financial advisor to DCG and a Hogan Lovells team led by Bill Curtin served as legal advisor to DCG on the transaction.

About Dave Cantin Group

Headquartered in New York, NY, The Dave Cantin Group (DCG) is a leading advisor to retail automotive groups and their owners. The Company also serves a variety of adjacent industries including automotive, motorcycle, powersports, heavy trucks, and recreational vehicles. DCG caters to the financial, transactional, and advisory needs of its clients throughout the dealership lifecycle, with particularly deep expertise as an advisor on both the buy-side and the sell-side of the M&A process. Through its media division, DCG produces the #1 downloaded automotive podcast, Dealer News Today. The company’s nonprofit partner, DCG Giving, funds child and adolescent cancer research and treatment in communities nationwide through its support of the Children’s Oncology Group. For more information, please visit

About Kaltroco

Kaltroco is a private investment company committed to supporting the long-term growth of high-quality middle-market businesses. Established in 1994, Kaltroco is owned and funded by the family of a founding partner of one of the world’s leading private equity firms. By leveraging its far-reaching global network and its deep experience as an investor in businesses across multiple sectors and at various stages of development, Kaltroco is able to support both the domestic and international growth ambitions of portfolio company management teams. Kaltroco’s partnership-minded approach is rooted in its distinctive, evergreen capital base, which allows for unusually strong alignment with management shareholders and family and founder owners as they pursue their long-term value creation objectives.

Media Contacts
For Dave Cantin Group:

Katie Merx
Jennifer Hurson

A photo accompanying this announcement is available at

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Avance Gas Holding Ltd: Ex Dividend USD 0.50 today7.12.2023 07:01:00 CET | Press release

Hamilton, Bermuda, December 7, 2023 The shares in Avance Gas Holding Ltd (ticker: "AGAS") will be traded ex-dividend USD 0.50 as of today relating to the dividend for the third quarter of 2023. The dividend will be paid on December 15, 2023. For further information, please contact: Randi Navdal Bekkelund - Chief Financial Officer Tel: +47 23 11 40 00 Email: ABOUT AVANCE GAS Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGCs) and operates a fleet of fourteen modern ships including two dual fuel LPG newbuildings for delivery in early 2024 as well as four medium sized gas/ammonia carriers due for delivery in 2025 and 2026. For more information about Avance Gas, please visit This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook7.12.2023 07:00:00 CET | Press release

PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today in a great spot,” commented David Loew, Chief Executive Officer, Ipsen. “Our business has been transformed, with the focus on Specialty Care now supported by a stronger pipeline and momentum from our growth platforms, as well as a robust balance sheet and an external-innovation strategy yielding compelling results. Ipsen is now ready for its next phase of growth with several launches across multiple potential indications, providing more options for patients with high unmet medical needs. Our journey will be driven by the combination of the growth platforms, our new medicines and more external-innovation transactions to come. We will also continue to deliver on our ambitious sustainability objectives and road

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC7.12.2023 07:00:00 CET | Press release

New Drug Application granted priority review with PDUFA date set for June 10, 2024 European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor Investigational elafibranor is the first novel second-line treatment for primary biliary cholangitis (PBC) to be filed in E.U. and U.S. in nearly a decade PARIS, FRANCE, 07 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade. The target FDA PDUFA date under priority review is June 10, 2024. The European Medicines Agency (EMA) has also validated Ipsen’s Marketing Authorization Applica

Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage7.12.2023 07:00:00 CET | Press release

Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer (CTO). Both will join the six-member Executive Committee effective January 1, 2024. “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European Commission. In a staged roll-out across the key European markets, launches will follow in the UK and France later that year, with Spain and Italy scheduled to launch in early 2025,” said Dario Eklund, CEO of Santhera. “With Geert Jan and Marc joining the Executive Committee, we are leveraging the existing expertise within our leadership team and are elevating the commercial and supply chain functions to their level of importance as we enter the commercial market.” Geert Jan van Daal, MD, PhD, has held v

Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology7.12.2023 03:30:00 CET | Press release

R&D Day Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology Details strong pipeline including Sanofi’s record 12 blockbuster opportunities under clinical evaluation: 9 innovative medicines and vaccines with €2 to 5 billion peak sales potential, and 3 ‘pipeline-in-a-product’ assets with a potential of over €5 billion peak sales Strategic transformation through R&D features potential multi-indication assets such as amlitelimab, frexalimab and the oral TNFR1si intended to address unmet patient needs in markets with low penetration of advanced therapiesEnhanced R&D focus aims to deliver a 50% increase in Phase 3 trials in 2024 and 2025 as well as 25 mid- to late-stage read-outs over the next 2 yearsAmbition to become an immunology powerhouse driven by recent and future launched pharma assets, generating over €10 billion in annual sales by 2030, in addition to the strong growth of